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Abstract: The PLEX-ID/Flu assay has been recently developed to enable the detection and typing of influenza viruses 
based on the RT-PCR/electrospray ionization mass spectrometry technology. 
This novel assay was evaluated for typing performance on 201 positive influenza A or B nasopharyngeal swab specimens 
(NPS) detected by real-time RT-PCR during the 2010-2011 season. The PLEX-ID/Flu assay detected and characterized 
91.3% and 95.3% of all influenza A and B samples, respectively. All non-typeable influenza A and B specimens by the 
assay showed low viral loads with threshold cycle values  33. Taken together, and although our results need to be 
confirmed by further prospective studies, the PLEX-ID/Flu assay detected positively and gave a typing result for 93% of 
all NPS detected positively by real-time RT-PCR, thus suggesting a potential role for influenza virus surveillance among 
other techniques. 
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INTRODUCTION 
  The World Health Organization (WHO) Global Influenza 
Surveillance and Response System provides essential 
information on the types and variants of influenza viruses 
circulating worldwide. Direct detection and identification of 
influenza strains from clinical samples are mostly performed 
by using specific real-time PCR assays and, less frequently, 
by culture-based methods [1, 2]. Genotyping or phenotyping 
characterization of positive cases is performed by sequencing 
classical PCR amplicons (requiring multiple primer pairs), 
followed by phylogenetic analysis, or hemagglutinin 
inhibition assay, respectively. 
  The influenza A(H1N1)pdm pandemic in 2009 resulted 
in the development of a number of assays, such as 
single/multiplex real-time RT-PCR [3-6] or microarray 
systems [7, 8], allowing the rapid detection and typing of 
influenza virus in human specimens. Sensitive and rapid 
diagnostic or typing assays are essential for appropriate 
patient management, particularly high risk patients, and the 
use of appropriate antiviral therapy. 
  RT-PCR/electrospray ionization mass spectrometry (ESI-
MS) assays were developed recently to enable the potential 
detection and typing of microbial agents, including influenza 
[9-14], during the same flow procedure [15-17]. This 
technology relies on the analysis of nucleotide base   
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composition signatures of highly variable selected regions 
based on the measurement of the molecular weight of PCR 
amplicons [12, 18]. 
  A first version of the influenza assay (Abbott Molecular, 
Des Plaines, IL, USA) performed on the T5000 instrument 
(Ibis/Abbott, Carlsbad, CA, USA) was validated for 
influenza A (including A(H3N2) and H5N1) and B isolates 
collected between 1999 and 2006 [13]. Sensitivity and 
specificity were estimated to reach 97% and 98%, 
respectively. ESI-MS analysis was also capable of 
identifying viral reassortments or co-infections (i.e., a mixed 
population). More recently, this assay reported a sensitivity 
and specificity of 94.1% and 97%, respectively, for 
A(H1N1)pdm detection [11]. Since then, the assay has been 
redesigned and updated. This “PLEX-ID/Flu assay” includes 
one pan-influenza primer set targeting the PB1 segment, five 
pan-influenza-A primer pairs targeting individually NP, M1, 
PA, PB2 and NS1 genes, one pan-influenza B primer pair 
targeting the PB2 segment, and two additional primer pairs 
targeting two surface antigens HA (H1) and NA (N1) genes 
[12]. 
  The PLEX-ID platform was used to perform a pilot 
evaluation for the detection and subtyping or lineage 
characterization of human influenza virus types A and B, 
respectively. For this, nasopharyngeal swab specimens 
(NPS) collected from a network of more than 80 
practitioners participating actively to the clinical surveillance 
of influenza cases in Switzerland and screened for influenza 
during the 2010-2011 season were used as follows. After 
viral genome extraction using the NucliSENS easyMAG 
(bioMérieux, Geneva, Switzerland), the following four one-
step real-time RT-PCR assays were applied for the routine Evaluation of a RT-PCR /ESI-MS Influenza Assay  The Open Virology Journal, 2012, Volume 6    65 
screening: the CDC pan-influenza A specific real-time RT-
PCR assay [19] considered as a reference assay for influenza 
type A surveillance by the WHO, and three in-house 
developed assays specific for A(H1N1)pdm (Swine H1 GE), 
influenza A(H3N2) (A/H3), and influenza B (InfB MP) 
detection (supplementary Table 1) all validated on WHO 
quality controls. Each week, a batch of 22 or 46 influenza-
positive specimens (according to the number of available 
specimens) were tested with the PLEX-ID/Flu assay in 
parallel to the usual real-time RT-PCR assays performed by 
the Swiss National Reference Centre for Influenza. NPS 
were selected blind of the real-time RT-PCR threshold cycle 
(CT) values and the type of influenza (influenza A or B). For 
each assay, specific positive and negative internal controls 
were included systematically in each run to rule out any 
potential PCR inhibitors or contaminations, respectively. 
  Between December 2010 and February 2011, 201 
specimens that revealed influenza- positive by real-time RT-
PCR (115 influenza A, 86 influenza B) were assessed with 
the PLEX-ID/Flu assay (Table 1), which is commercially 
available upon request. The analysis included also 29 
influenza-negative NPS as negative controls. Most PLEX-ID 
experiments could be performed within 24 h following real-
time RT-PCR analysis (181/230), whereas 49 NPS had to be 
analyzed after storage for 72 h at 4°, or after a freeze-thaw 
cycle. For influenza A real-time RT-PCR-positive 
specimens, the PLEX-ID/Flu assay could subtype 
successfully 105/115 cases (91.3%), corresponding to 
101/111 A(H1N1)pdm (91%; all related to A/Hong 
Kong/2212/10 (H1N1)p) and 4/4 A(H3N2) (100%; all 
related to A/Perth/16/2009 (H3N2)) viruses. For influenza B 
real-time RT-PCR-positive specimens, the assay 
characterized successfully the lineage for 82/86 cases 
(95.3%; 73 and 9 specimens appear related to 
HongKong/514/2009 and Wisconsin/01/10 strains, 
respectively). Of note, the PLEX-ID/Flu assay’s subtyping 
or lineage characterization for A(H3N2) and type B 
specimens, respectively, is less accurate than for 
A(H1N1)pdm specimens since HA and NA genes are not 
included in the analysis. Taken together, the PLEX-ID/Flu 
assay detected positively and gave a typing/lineage 
characterization result for 93% of all NPS detected positively 
by real-time RT-PCR. Positive results obtained by both 
methods were always in agreement. All non-typeable 
influenza A and B specimens by the PLEX-ID/Flu assay 
showed relatively low viral loads with CT values  33 
obtained with the screening real-time RT-PCR assays. 
  The typing performance of the PLEX-ID/Flu assay 
versus the Sanger-based sequencing method was then 
compared for all influenza specimens with low viral loads 
(CT values  30; 19 influenza A and 18 influenza B-positive 
NPS; Table 2). Briefly, for the Sanger-based sequencing 
method, reverse transcription was performed in the presence 
of Uni12w or BUni11w primers updated from [20] and [21], 
respectively, provided by Prof. Rod Daniels (MRC, 
London). Part of the influenza HA-1 gene was then 
amplified as follows: for influenza A viruses, a first PCR 
reaction was performed with cswHAF1 and cswHAR1264 
primers, followed by two nested PCR reactions with 
cswHAF31/cswHAR873 and cswHAF451/cswHAR1264 
primer pairs (supplementary Table 1). For influenza B 
viruses, BHA1F1 and BHA1R1 primers were used for the 
first PCR reaction, followed by a nested PCR using the 
BHA25/BHAF primer pair. Sequencing was performed with 
ABI Prism 3130XL DNA Sequencer (Applied Biosystems, 
Rotkreuz, Switzerland) and analyzed with the Geneious 
program (Biomatters, Auckland, New Zealand). 
Table  1.  Comparison of the PLEX-ID/Flu Assay 
Performance Versus Real-Time PCR Assays for 
Influenza A and B Virus Detection and 
Subtyping/Lineage Characterization from 
Nasopharyngeal Respiratory Specimens 

Real-Time PCR Assay
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Real-Time PCR Assay
Influenza B
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86 29 115
The same 29 negative controls are used in both comparisons (marked *). ND: not done. 
 
  Among these 37 specimens, the PLEX-ID/Flu assay was 
able to subtype 9/19 influenza A (47.5%) and characterize 
the lineage for 14/18 influenza B (77.8%). The Sanger-based 
sequencing method was able to subtype 13/19 influenza A 
(68.4%) and identify the lineage for 9/18 influenza B (50%). 
Therefore, for these selected specimens, the PLEX-ID/Flu 
assay demonstrates a sensitivity for influenza B virus lineage 
characterization that is at least similar to the Sanger-based 
method, which is directly dependent on conditions used for 
viral genome amplification by classical PCR. However, the 
latter appears more sensitive for influenza A subtyping under 
these conditions. This observation can be explained by the 
PLEX-ID/Flu assay algorithm that requires the analysis of 
nucleotide base composition signatures of a minimum of 
three positive PCRs out of eight independent primer pairs 
present in the assay, with the mandatory coupling of 
detection and subtyping processes, for influenza A specimen 66    The Open Virology Journal, 2012, Volume 6  Cordey et al. 
analysis. Therefore, the typing constraint of the PLEX-
ID/Flu assay explains partially the higher influenza A 
subtyping performance of the Sanger-based method for low 
viral load specimens. Indeed, 9/10 influenza A NPS detected 
positive by real-time RT-PCR could not be subtyped with 
the PLEX-ID/Flu assay, although one or two positive PCR 
signals were observed. Although the minimal requirement of 
three independent PCR signals for subtyping was not 
obtained, specific influenza A PCR amplifications were 
detected, suggesting a sensitivity threshold close to the real-
time RT-PCR. 
  Based on a selection of positive NPS collected in 
Switzerland during the 2010-2011 influenza season, this 
study suggests that the PLEX-ID/Flu assay is a convenient 
platform for the detection, typing, and subtyping (lineage 
characterization for influenza B) of circulating influenza 
viruses. The detection rate observed with the PLEX-ID 
platform, as well as the subtyping or lineage characterization 
of human influenza virus types A and B tends to suggest that 
it might play a role in the near future in most routine 
laboratories, but this needs to be confirmed in prospective 
and large comparative studies. In addition, the sensitivity of 
the PLEX-ID/Flu observed in this study could be increased if 
any positive PCR results were considered and if the typing 
result is not a requirement. However, this pilot study has 
intrinsic limitations mainly related to the fact that only real-
time RT-PCR-positive specimens were selected initially. 
This precludes any appropriate evaluation of the respective 
sensitivity or specificity of the method. Compared to 
sequence analysis, the PLEX-ID/Flu assay has also 
limitations in terms of identification of specific mutations 
potentially involved in antiviral resistance, as well as drifted 
strains. Finally, the lack of accurate typing concerning the 
HA and NA genes is a major drawback and possibly limits 
the use of this assay as a first line diagnostic tests. 
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